Health & Biotech
Dr Boreham’s Crucible: With five trials and $100m, cancer-hunter Clarity’s future is clear
Health & Biotech
Opyl is ready to scale up AI platform Opin after delivering full-year revenue growth
Health & Biotech
ScoPo’s Powerplays: ‘Ansell is a buy’, while all eyes are on ImpediMed’s upcoming publication
Health & Biotech
MGC Pharma signs US distribution deal, lands access to the world’s largest healthcare market
Health & Biotech
ASX Health Stocks: Acrux flags testosterone solution with an armpit application, Clinuvel posts record revenues
Health & Biotech
Health Kick: Wellnex CEO George Karafotias discusses the company’s wellness pivot, major licensing deal and new product suite
Health & Biotech
Dimerix shares up 8% on DMX-200 FSGS Phase 3 trial news
Health & Biotech
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit
Health & Biotech
ASX Health Stocks: Nanosonics jumps almost 20% as revenue momentum picks up steam
Health & Biotech
Lean, mean and green: How ECS Botanics is capitalising on ‘explosive growth’ in medicinal cannabis
Health & Biotech
Why haven’t any ASX pot stocks got CBD on Australian pharmacy shelves yet? And when will we see them?
Health & Biotech
Incannex sets sights on US capital markets and prepares for a Nasdaq listing
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.